综述Overview

Pharmaceuticals is a strategic industry that bears on national life and health and combines livelihood attributes with technology attributes, and is also the main battleground of "hard technology" and "domestic substitution." In evaluating a pharmaceutical company, if one looks only at revenue, distribution and generic-drug companies naturally gain an advantage; if one looks only at profit, innovative-drug companies with high R&D investment (often in a loss-making period) are systematically undervalued; and if one looks only at market value, it is easily disturbed by capital sentiment and market cycles. Therefore, this ranking does not copy the positions of any public list, but uses underlying public data to independently build a "Scale + Quality + Innovation + Contribution" four-dimensional evaluation system to comprehensively evaluate about 30 representative pharmaceutical companies.

医药是关乎国民生命健康、兼具民生属性与科技属性的战略性行业，也是"硬科技"与"国产替代"的主战场。衡量一家医药企业，若仅看营收，则流通与仿制药企业天然占优；若仅看利润，则高研发投入的创新药企业（常处亏损期）被系统性低估；若仅看市值，又易受资本情绪与市场周期扰动。因此，本排名不摘抄任何公开榜单名次，而是用底层公开数据自建一套"规模 + 质量 + 创新 + 贡献"四维评价体系，对约 30 家代表性医药企业进行综合评价。

Evaluation results: Hengrui Medicine, Mindray Medical, CSPC Pharmaceutical Group, BeiGene, and Sino Biopharmaceutical rank in the top five. Overall, leading innovative-drug and medical-device companies that balance the four dimensions of scale, profitability, R&D intensity, and proprietary innovation output rank highest; purely distribution, purely generic, and purely agency companies rank lower because of their weaker innovation and contribution dimensions; and some biotech companies still in a loss-making period but with outstanding R&D investment and innovation pipelines are compensated on the innovation and contribution dimensions, ranking higher than their profit performance. The ranking data use approximate values from public knowledge such as listed-company annual reports and public market capitalization, all marked "subject to official sources," permanently free and public, for research and reference only.

评价结果：恒瑞医药、迈瑞医疗、石药集团、百济神州、中国生物制药位列前五。整体看，兼具规模、盈利能力、研发强度与自主创新产出"四维均衡"的头部创新药与器械企业居前；纯流通、纯仿制、纯代理的企业因创新与贡献维度偏弱而排名靠后；部分处于亏损期但研发投入与创新管线突出的生物科技企业，在创新与贡献维度上获得补偿，排名高于其利润表现。本排名数据采用上市公司年报、公开市值等公开知识的近似值，一律标注"以官方为准"，永久免费公开，仅供研究与参考。

医药行业企业排名Pharmaceutical Industry Enterprise Ranking

排名	企业	综合得分	规模	质量	创新	贡献	营收(亿)	净利(亿)	市值(亿)	研发(亿)	创新品(款)	梯队
1	恒瑞医药Hengrui Pharma	80.68	63.8	76.8	79.5	100.0	270	63	3200	60	12	A++
2	迈瑞医疗Mindray	77.44	67.9	100.0	68.7	66.7	350	115	3300	40	8	A++
3	石药集团CSPC Pharmaceutical Group	64.3	65.5	52.9	74.6	66.7	300	60	900	50	8	A++
4	百济神州BeiGene	62.84	63.8	41.9	100.0	50.0	270	-40	2100	130	6	A+
5	中国生物制药Sino Biopharmaceutical	61.11	64.4	34.1	68.7	83.3	280	30	650	40	10	A+
6	上海医药Shanghai Pharmaceuticals	53.54	100.0	44.1	56.3	25.0	2600	50	700	25	3	A+
7	复星医药Fosun Pharma	52.01	70.1	29.7	74.6	41.7	400	20	650	50	5	A+
8	药明康德WuXi AppTec	50.67	70.1	86.6	42.7	0.0	400	94	2600	15	0	A+
9	智飞生物Zhifei Biological	49.99	70.1	57.1	50.3	25.0	400	80	700	20	3	A+
10	翰森制药Hansoh Pharma	47.78	49.4	37.8	56.3	50.0	110	30	800	25	6	A+
11	科伦药业Kelun Pharmaceutical	40.88	59.0	27.2	50.3	33.3	200	25	500	20	4	A
12	信达生物Innovent Biologics	39.83	44.3	19.6	50.3	50.0	80	-8	600	20	6	A
13	华东医药Huadong Medicine	39.49	70.1	28.5	42.7	25.0	400	28	500	15	3	A
14	白云山Guangzhou Baiyunshan Pharmaceutical	36.82	80.1	33.7	26.0	16.7	750	40	500	8	2	A
15	丽珠集团Livzon Group	32.69	50.8	18.7	42.7	25.0	120	20	350	15	3	A
16	云南白药Yunnan Baiyao	31.93	69.7	46.1	0.0	16.7	390	40	1000	3	2	A
17	华润三九China Resources Sanjiu	30.17	62.6	30.2	26.0	8.3	250	28	550	8	1	A
18	康方生物Akeso	27.56	28.7	16.3	42.7	25.0	30	-5	500	15	3	A
19	华海药业Huahai Pharmaceutical	26.31	47.9	8.3	31.9	25.0	100	10	250	10	3	A
20	片仔癀Pien Tze Huang	25.99	47.9	47.8	0.0	8.3	100	30	1400	3	1	A
21	贝达药业Betta Pharmaceuticals	24.79	28.7	2.2	31.9	41.7	30	5	200	10	5	B
22	沃森生物Walvax Biotechnology	22.23	33.3	9.4	26.0	25.0	40	5	300	8	3	B
23	天士力Tasly	21.67	44.3	2.2	31.9	16.7	80	5	200	10	2	B
24	华兰生物Hualan Biological Engineering	21.17	39.7	18.9	13.6	16.7	60	15	400	5	2	B
25	同仁堂Tong Ren Tang	21.04	57.3	25.0	0.0	8.3	180	16	550	3	1	B
26	君实生物Junshi Biosciences	20.44	17.6	0.0	42.7	25.0	15	-20	200	15	3	B
27	百利天恒Baili Tianheng	19.57	0.0	24.7	31.9	16.7	5	0	800	10	2	B
28	康泰生物BioKangtai	19.08	28.7	8.3	18.4	25.0	30	10	250	6	3	B
29	上海莱士Shanghai RAAS	18.03	42.2	25.0	0.0	8.3	70	20	500	3	1	B
30	传奇生物Legend Biotech	14.47	0.0	19.6	26.0	8.3	5	0	600	8	1	B

表内营收、净利润、市值、研发投入、创新产品数均为公开常识近似值，以官方为准；"净利"为负表示亏损期（质量维度该项记 0）。
Revenue, net profit, market cap, R&D investment, and number of innovative products in the table are all public approximate values, subject to official figures; a negative 'Net Profit' indicates a loss-making period (that item scores 0 in the quality dimension).

算法详细论述Methodology

一、评价依据

The value implications of a pharmaceutical company differ from those of an ordinary industrial enterprise: drugs are characterized by long R&D cycles, large investment, and high failure rates, so there is a significant intergenerational mismatch between "today's profit" and "tomorrow's innovation." Therefore, this algorithm characterizes a company's comprehensive competitiveness from four dimensions:

医药企业的价值内涵与一般工业企业不同：药品具有研发周期长、投入大、失败率高的特点，"今天的利润"与"明天的创新"之间存在显著的代际错位。因此，本算法从四个维度刻画企业综合竞争力：

规模：以营业收入衡量，反映企业的市场体量、渠道能力与抗风险底盘。
质量：以净利润与总市值双指标衡量，反映盈利能力（现金流与股东回报）与资本市场认可度。
创新：以研发投入衡量，反映企业对技术长周期的持续投入意愿与研发能力储备。
贡献：以自主创新产品（1 类新药、创新生物药、原研器械、创新疫苗）数量衡量，是 CPPPS 的特色维度——它度量企业"自主创新"而非"仿制/代理/贴牌"给行业与国家带来的真实贡献，国际通行榜单普遍缺失此维度。

二、数学模型

Each indicator is first mapped to [0,1] via range standardization and then combined by weighted summation. For large-span scale indicators (revenue, market value, and R&D investment, with spans of up to several hundred times), the logarithm is taken before standardization to avoid domination by leading companies and restore the true order-of-magnitude differences:

各指标先经极差标准化映射到 [0,1]，再加权求和。针对规模类大跨度指标（营收、市值、研发投入，跨度可达数百倍），先取对数再标准化，避免头部企业垄断、还原数量级的真实差异：

营收′ = norm01[ log₁₀(营收) ]，市值′ = norm01[ log₁₀(市值) ]，研发′ = norm01[ log₁₀(研发) ]

Because net profit can be negative (losses), negative values are first truncated to 0 during standardization (loss-making companies score 0 on this item), and then range-standardized; the number of proprietary innovative products is linearly standardized.

净利润因存在亏损（负值），标准化时先将负值截为 0（亏损企业该项计 0 分），再极差标准化；自主创新产品数取线性标准化。

规模 = 100 × 营收′ 质量 = 100 × ( 0.5 × 净利′ + 0.5 × 市值′ ) 创新 = 100 × 研发′，贡献 = 100 × 创新产品′ 综合得分 = 0.20 × 规模 + 0.30 × 质量 + 0.25 × 创新 + 0.25 × 贡献

The weight design reflects the value orientation of "quality first, equal emphasis on innovation and contribution, and scale as the floor": quality accounts for 30% (profit and market value each half), innovation and contribution together account for 50% (25% each), and scale accounts for 20%. This structure ensures that "distribution/generic companies with high profit but low R&D and low innovation" do not monopolize the top by virtue of large revenue, while "biotech companies with high R&D and high innovation but not yet profitable" can be fairly compensated on the innovation and contribution dimensions.

权重设计体现"质量优先、创新与贡献并重、规模兜底"的价值取向：质量占 30%（盈利与市值各半），创新与贡献合计占 50%（各 25%），规模占 20%。这一结构使得"高利润但低研发、低创新的流通/仿制企业"不会因营收大而垄断榜首，"高研发、高创新但尚未盈利的生物科技企业"也能在创新与贡献维度得到公平补偿。

三、指标与权重依据

指标	方向	处理	权重	所属维度	依据
营业收入	正向	log₁₀	0.20	规模	市场体量与抗风险底盘
净利润	正向	亏损截0	0.15	质量	盈利能力与现金流
总市值	正向	log₁₀	0.15	质量	资本市场认可度
研发投入	正向	log₁₀	0.25	创新	持续研发意愿与能力储备
自主创新产品数	正向	线性	0.25	贡献	自主创新贡献（CPPPS 特色）

Scope note: for the "proprietary innovative products" of the contribution dimension, pharmaceutical companies are counted by the number of approved Class 1 new drugs and innovative biologics; medical-device and vaccine companies are counted by their original/innovative products; and service-type R&D outsourcing companies score 0 because they do not hold proprietary drugs (their contribution is reflected through R&D investment, revenue, and profit). This scope is intended to strip away the inflation of rankings caused by "imitation, agency, and private labeling," highlighting proprietary innovation capability.

口径说明：贡献维度的"自主创新产品"对制药企业计 1 类新药与创新生物药获批数量，对医疗器械、疫苗企业按其原研/创新产品计，对服务型研发外包企业因其不持有自主药品而计 0（其贡献通过研发投入、营收与利润体现）。此口径旨在剥离"仿制、代理、贴牌"对排名的虚增，突出自主创新能力。

四、数据来源与局限性

Operating revenue and net profit use approximate values from listed-company annual reports (disclosed by the Shanghai, Shenzhen, and Hong Kong exchanges); total market value uses approximate values in public-market terms; R&D investment uses approximate values from the "R&D expense" item in annual reports; and the number of proprietary innovative products is approximately counted based on NMPA approval information for new drugs/innovative medical devices/innovative vaccines. All values are approximate values from public common knowledge, uniformly marked "subject to official sources." This model does not include deeper indicators such as R&D intensity (R&D/revenue ratio), patent counts, overseas/licensing revenue, and medical-insurance negotiation; moreover, there are timing and statistical differences in the standards for market value and innovative products. The ranking is for research and reference only.

营业收入、净利润采用上市公司年报（上交所、深交所、港交所披露）公开近似值；总市值采用公开市场口径近似值；研发投入采用年报"研发费用"科目近似值；自主创新产品数量依据国家药品监督管理局（NMPA）新药/创新医疗器械/创新疫苗获批信息近似统计。所有数值均为公开常识近似值，一律标注"以官方为准"。本模型未纳入研发强度（研发/营收比）、专利数量、出海/授权许可收入、医保谈判等更深层指标，且市值、创新产品口径存在时点与统计差异，排名仅供研究与参考。

五、参考文献

各上市公司年度报告（上交所、深交所、港交所信息披露平台）。
国家药品监督管理局（NMPA）：药品/医疗器械/疫苗注册审批与创新产品公示。
国家医疗保障局：国家医保药品目录与谈判准入信息。
中共中央、国务院：《"健康中国2030"规划纲要》。
国务院：《"十四五"医药工业发展规划》。
中国医药创新促进会等行业协会：行业统计数据（近似值参考）。
公开市场总市值数据（中证、港交所口径，近似值）。

说明Notes

本版采用"规模 + 质量 + 创新 + 贡献"四维自有算法（非摘抄公开榜单名次）：①规模维度以营业收入、取 log₁₀ 极差标准化，避免头部垄断；②质量维度以净利润（亏损截 0）与总市值各半加权；③创新维度以研发投入取 log₁₀ 标准化；④贡献维度（CPPPS 特色）以自主创新产品（1 类新药/创新生物药/原研器械/创新疫苗）数量计，剥离仿制、代理、贴牌对排名的虚增。综合得分 = 0.20×规模 + 0.30×质量 + 0.25×创新 + 0.25×贡献。数据为公开常识近似值，以官方为准。本排名永久免费公开，永不卖榜。
This edition adopts the "scale + quality + innovation + contribution" four-dimension proprietary algorithm (not reproducing public list rankings): ① The scale dimension uses operating revenue with log₁₀ min-max standardization to avoid top-tier monopoly; ② The quality dimension equally weights net profit (losses truncated to 0) and total market cap; ③ The innovation dimension standardizes R&D investment with log₁₀; ④ The contribution dimension (CPPPS signature) counts self-developed innovative products (Class-1 new drugs/innovative biologics/original devices/innovative vaccines), stripping away the ranking inflation from generics, agency, and private-label products. Composite score = 0.20×scale + 0.30×quality + 0.25×innovation + 0.25×contribution. Data are public approximate values, subject to official figures. This ranking is permanently free and public, and rankings are never sold.

医药行业企业排名Pharmaceutical Industry

综述Overview

分层梯队Tiers